David Lebwohl

David Lebwohl

UNVERIFIED PROFILE

Are you David Lebwohl?   Register this Author

Register author
David Lebwohl

David Lebwohl

Publications by authors named "David Lebwohl"

Are you David Lebwohl?   Register this Author

37Publications

1292Reads

44Profile Views

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

N Engl J Med 2018 02;378(5):439-448

From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia (S.L.M., S.A.G.) - all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, and the Pauline Allen Gill Center for Cancer and Blood Disorders, Children's Health, Dallas (T.W.L.); the Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo (J.B.); the Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu Barcelona, Barcelona (S.R.); the Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City (M.B.); the Department of Pediatrics, Faculty of Medicine, University of Montreal, and the Hematology Oncology Division and Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal (H.B.), and the Division of Haematology/Oncology/Bone Marrow Transplantation, Hospital for Sick Children, Toronto (J.K.) - all in Canada; the Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany (P.B.); the Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis (M.R.V., H.E.S.); Children's Mercy Hospital and Clinics, Kansas City, MO (G.D.M.); Aflac Cancer and Blood Disorders Center, Emory University, Atlanta (M.Q.); the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, and the Cancer Research Institute Ghent (CRIG), Ghent, Belgium (B.D.M.); the Department of Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, Japan (H.H.); the Department of Pediatrics, Stanford University School of Medicine, Stanford (K. Schlis, K.L.D.), and the Division of Hematology, Oncology, Blood and Marrow Transplant, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles (M.A.P.) - all in California; the Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, NC (P.L.M.); Oregon Health and Science University, Portland (E.R.N.); C.S. Mott Children's Hospital, Ann Arbor, MI (G.A.Y.); the Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna (C.P.); University Hospital Robert Debré and University Paris Diderot (A. Baruchel), and Saint-Louis Hospital and University Paris Diderot (N.B.), Paris; the Royal Children's Hospital, Melbourne, VIC, Australia (F.M.); Clinica Pediatrica Universita degli Studi di Milano Bicocca, Monza, Italy (A. Balduzzi); and Novartis Pharmaceuticals (P.W., T.T., M.L., Y.Z., K. Sen, D.L.) and Novartis Institutes for Biomedical Research (K.T.M.) - both in East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709866DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996391PMC
February 2018

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

J Clin Oncol 2013 Nov 16;31(31):3935-43. Epub 2013 Sep 16.

Atsushi Ohtsu, National Cancer Center Hospital East, Kashiwa; Keisho Chin, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan; Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX; Tarek Sahmoud, Heind Smith, Syed Rizvi, David Lebwohl, Novartis Pharmaceuticals, Florham Park, NJ; Yu-Xian Bai, Tumor Hospital of Harbin Medical University, Harbin; Hong-Ming Pan, Sir Run Run Shaw Hospital, Zhejiang; Lin Shen, Peking University Cancer Hospital, Beijing, People's Republic of China; Yung-Jue Bang, Seoul National University College of Medicine; Hyun-Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yeul Hong Kim, Korea University Anam Hospital, Seoul, South Korea; Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; David Ferry, New Cross Hospital, Wolverhampton, United Kingdom; Niall C. Tebbutt, Austin Health, Heidelberg, Australia; Salah-Eddin Al-Batran, Institute for Clinical Oncology Research, Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany; Chiara Costantini, Novartis Pharma AG, Basel, Switzerland; Eric Van Cutsem, University Hospitals Leuven and KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.3552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950503PMC
November 2013

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Ann N Y Acad Sci 2013 Jul 9;1291:14-32. Epub 2013 May 9.

Novartis Pharmaceuticals Corporation, Florham Park, New Jersey 07932, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nyas.12122DOI Listing
July 2013

Research and innovation in the development of everolimus for oncology.

Expert Opin Drug Discov 2011 Mar 17;6(3):323-38. Epub 2011 Feb 17.

Novartis Pharmaceuticals, Inc., 180 Park Avenue, Florham Park, NJ 07932, USA +1 862 778 7218 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17460441.2011.558079DOI Listing
March 2011

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

Cancer J 2009 Sep-Oct;15(5):386-94

Novartis Pharmaceuticals Corporation, Florham Park, NJ 07932, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3181b9c5ecDOI Listing
April 2010

Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.

Semin Oncol 2006 Apr;33(2 Suppl 7):S18-25

Novartis Institutes For BioMedical Research, Oncology Basel, Novartis Pharma AG, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.03.024DOI Listing
April 2006

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

Invest New Drugs 2005 Jan;23(1):79-84

Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:DRUG.0000047109.76766.84DOI Listing
January 2005

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.

Clin Cancer Res 2004 Feb;10(4):1289-98

Albert Einstein College of Medicine, Department of Molecular Pharmacology, and Albert Einstein Comprehensive Cancer Center, Bronx, New York 10461, USA.

View Article

Download full-text PDF

Source
February 2004

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

Gynecol Oncol 2002 Feb;84(2):327-31

National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2001.6409DOI Listing
February 2002